Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
AiCuris
AiCuris
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Graphs and graph data science in drug discovery
Life sciences data expert Dr Alexander Jarasch discusses what work being done at the Institut de Recherches Servier can teach us about using modern data technologies for early...
Why smaller CDMOs should enhance their operational efficiency now: a CPHI expert guide
CPHI experts advise smaller CDMO's to invest in supply chain resilience, friend shoring and AI to keep up with the predicted uptick in funding for 2025
CPI collaborates with industry leaders to expedite drug manufacturing via digitisation
Digitising manufacturing technologies could allow enhanced ability to scale production, reduce costs and expedite the process
Janssen to adopt Johnson & Johnson brand as the company celebrates 100 years of UK operation
The company's pharmaceutical and medical technology segments will combine under the Johnson & Johnson brand name in the UK
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Ingredients
AiCuris initiates clinical development of AIC499, a novel resistance-breaking antibiotic
Programme supported by the Innovative Medicines Initiative
You need to be a subscriber to read this article.
Click here
to find out more.
Research & Development
Can new discoveries prevent an antibiotic Armageddon?
Governments are waking up to the catastrophe of drug resistance and healthcare without antibiotics. But is extra funding the answer or could the pharma industry be doing more?
Research & Development
COMBACTE-MAGNET project aims to stimulate antibiotic development in Europe
Seven-year project brings together 33 European academic partners and five pharmaceutical companies
Regulatory
Antiviral agent – letermovir
Cytomegalovirus (CMV) can cause severe difficulties in patients with compromised immune systems, such as people with HIV infection or those who are undergoing organ or bone marrow transplantation
Subscribe now